Wild Swing Trades 📈

Mean reversion · October 2, 2026 close The Oversold Quality Bounce is a mean-reversion sleeve, not a value-trap basket. You buy a business whose economics are still intact after the price has overshot on a narrative, a growth scare, or a sector de-rating — and only when the tape says selling is tired. Not investment advice. This is an educational write-up of a screen, not a recommendation to buy, sell, or hold any security. Prices, ratios, RSI readings, and street targets are point-in-time figures as of the October 2, 2026 close and will be stale by the time you read this. Technical levels fail. Consensus estimates get cut. You can lose money, including more than you expect on a “quality” name. Nothing here is personalized advice, a solicitation, or a promise about future returns. Do your own work, and consider whether a trade fits your risk tolerance, time horizon, and tax situation. Applied to Booking Holdings (BKNG) , Colgate-Palmolive (CL) , Adobe (ADBE) , and Chewy...

Market note · October 1, 2026 Intellia (NASDAQ: NTLA) at $12.12: Coil, Not a Breakout A levels-and-scenarios playbook for the in-vivo CRISPR name. Tape read as of the October 1, 2026 close. Disclaimer. This is market commentary, not investment advice, a solicitation, or a recommendation to buy or sell any security. Biotech is binary. A safety headline, a trial delay, or a financing can gap through any stop. Scenario probabilities are subjective weights based on price structure, volume, and public disclosures as of October 1, 2026. They are not forecasts. Intellia is pre-commercial, cash-burning, and heavily shorted. Do your own research or consult a licensed adviser. Past performance is not indicative of future results. Intellia is coiling, not breaking out. At about $12.12 the stock is pinned on the 50-day moving average near $12 and still under the 200-day near $12.84. It is roughly 57 percent below the 52-week high of $28.25 and about 52 percent above the...

Market note · October 1, 2026 Compass (NYSE: COMP) at $9.10: Bounce, Not a Breakout A levels-and-scenarios playbook for the post-Anywhere real estate platform. Intraday read as of the October 1, 2026 session. Disclaimer. This is market commentary, not investment advice, a solicitation, or a recommendation to buy or sell any security. Scenario probabilities are subjective weights based on price structure, volume, and publicly reported fundamentals as of October 1, 2026. They are not forecasts. Compass is a high-beta stock (about 2.33) and can gap through stops, especially into the early-November earnings window. Quotes, analyst targets, short interest, and guidance change. Do your own research or consult a licensed adviser before acting. Past performance is not indicative of future results. Compass is bouncing, not breaking out. At about $9.10 the stock is still roughly 35 percent under the 52-week high of $1...

​ Math, Grind, and Micro-Capital: Building an Algo Trading Server from Scratch ​ When people ask me what my current journey feels like, I tell them it’s equal parts Π , The Pursuit of Happyness , and 21 . ​ It sounds dramatic until you break down what it actually takes to build an algorithmic trading infrastructure while trading a tiny account. You’re navigating raw mathematical obsession, unrelenting personal sacrifice, and high-stakes risk management—all at the same time. ​ Here is how those three forces intersect when you're building your future line by line. ​ ​ 1. The Π Element: Finding Order in Chaos ​ In Darren Aronofsky’s movie Π , the protagonist becomes consumed by the search for hidden patterns within numerical chaos. ​ When you start building a custom trading server, you experience that same mindset. You look at market data—millions of ticks, order book depth, fluctuating volatility—and realize that behind the noise lies structure, probability, and cycl...

Market structure  ·  Short-interest deep dive Four Crowded Shorts, Four Very Different Setups A briefing on Groupon, Karyopharm, The Children’s Place, and Immuneering — why high short interest is not a strategy, which names actually have squeeze mechanics, and where the fundamental landmines sit. Published September 30, 2026  ·  ~14 minute read  ·  Short-interest vintage: FINRA settlement of September 15, 2026. Prices through September 29–30, 2026. Disclaimer — read this first. This article is for informational and educational purposes only. It is not investment advice, a recommendation to buy or sell any security, or an offer or solicitation. Nothing here is a prediction that any of these stocks will squeeze, rise, or survive. Groupon (GRPN) , Karyopharm Therapeutics (KPTI) , The Children’s Place (PLCE) , and Immuneering (IMRX) are highly speculative securities. They can gap 30–80% in a session in either di...